Sofosbuvir and Ribavirin for 6 Weeks Is Not Effective Among People With Recent Hepatitis C Virus Infection: The DARE-C II Study
Marianne Martinello, Edward Gane, Margaret Hellard, Joe Sasadeusz, David Shaw, Kathy Petoumenos, Tanya Applegate, Jason Grebely, Laurence Maire, Philippa Marks, Gregory J Dore, Gail V Matthews
Hepatology | WILEY | Published : 2016
The Kirby Institute is funded by the Australian Government Department of Health and Ageing. The views expressed in this publication do not necessarily represent the position of the Australian government. The Burnet Institute receives funding from the Victorian Operational Infrastructure Support Program. Research reported in this publication was supported by Gilead Sciences Inc. as an investigator-initiated study. The content is solely the responsibility of the authors. Jason Grebely and Gail Matthews are Supported by the National Health and Medical Research Council (Career Development Fellowships to J.G. and G.V.M., Practitioner Fellowships to G.J.D., and a Principal Research Fellowship to M.H.).